Treatment of chronic hepatitis B virus infection in resource-constrained settings: expert panel consensus

Simple item page
dc.contributor.authorWiersma, Steven T.
dc.contributor.authorMcMahon, Brian
dc.contributor.authorPawlotsky, Jean-Michel
dc.contributor.authorThio, Chloe L.
dc.contributor.authorThursz, Mark
dc.contributor.authorLim, Seng Gee
dc.contributor.authorOcama, Ponsiano
dc.contributor.authorEsmat, Gamal
dc.contributor.authorMaimuna, Mendy
dc.contributor.authorBell, David
dc.contributor.authorVitoria, Marco
dc.contributor.authorEramova, Irina
dc.contributor.authorLavanchy, Daniel
dc.contributor.authorDusheiko, Geoff
dc.date.accessioned2022-04-30T21:37:32Z
dc.date.available2022-04-30T21:37:32Z
dc.date.issued2011
dc.description.abstractMost of the estimated 350 million people with chronic hepatitis B virus (HBV) infection live in resource-constrained settings. Up to 25% of those persons will die prematurely of hepatocellular carcinoma (HCC) or cirrhosis. Universal hepatitis B immunization programmes that target infants will have an impact on HBV-related deaths several decades after their introduction. Antiviral agents active against HBV are available; treatment of HBV infection in those who need it has been shown to reduce the risk of HCC and death. It is estimated that 20–30% of persons with HBV infection could benefit from treatment. However, drugs active against HBV are not widely available or utilized in persons infected with HBV. Currently recommended antiviral agents used for treatment of human immunodeficiency virus (HIV) infection do not adequately suppress HBV, which is of great concern for the estimated 10% of the HIV-infected persons in Africa who are co-infected with HBV. Progressive liver disease has been shown to occur in co-infected persons whose HBV infection is not suppressed. In view of these concerns, an informalWorld Health Organization consultation of experts concluded that: chronic HBV is a major public health problem in emerging nations; all HIV-infected persons should be screened for HBV infection; HIV/HBV co-infected persons should be treated with therapies active against both viruses and that reduce the risk of resistance; standards for the management of chronic HBV infection should be adapted to resource-constrained settings. In addition, a research agendum was developed focusing on issues related to prevention and treatment of chronic HBV in resource-constrained settings.en_US
dc.identifier.citationWiersma, S. T., McMahon, B., Pawlotsky, J. M., Thio, C. L., Thursz, M., Lim, S. G., ... & Dusheiko, G. (2011). Treatment of chronic hepatitis B virus infection in resource‐constrained settings: expert panel consensus. Liver International, 31(6), 755-761. DOI:10.1111/j.1478-3231.2010.02373.xen_US
dc.identifier.issn1478-3223
dc.identifier.other10.1111/j.1478-3231.2010.02373.x
dc.identifier.urihttps://nru.uncst.go.ug/handle/123456789/3084
dc.language.isoenen_US
dc.publisherLiver International,en_US
dc.subjectHepatitis Ben_US
dc.subjectResource-constrained settingsen_US
dc.subjectTreatmenten_US
dc.titleTreatment of chronic hepatitis B virus infection in resource-constrained settings: expert panel consensusen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Liver International - 2011 - Wiersma - Treatment of chronic hepatitis B virus infection in resource‐constrained settings .pdf
Size:
137.05 KB
Format:
Adobe Portable Document Format
Description:
Article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Medical and Health Sciences